The FN1-SPARC-axis is of particular interest as SPARC expression has been shown to be reduced in CML patients, while it is increased in the serum of CML patients after imatinib treatment (Giallongo et al., 2013; Nian et al., 2022). Here, FN1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.